GWSA
TTNP

Global Wealth Strategies & Associates’s Titan Pharmaceuticals TTNP Stock Holding History

Global Wealth Strategies & Associates’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2
Closed -$3 – 437
2026
Q1 		$3 Hold
2
– – ﹤0.01% 542
2025
Q4 		$3 Hold
2
– – ﹤0.01% 548
2025
Q3 		$10 Hold
2
– – ﹤0.01% 485
2025
Q2 		$8 Hold
2
– – ﹤0.01% 377
2025
Q1 		$7 Hold
2
– – ﹤0.01% 471
2024
Q4 		$7 Hold
2
– – ﹤0.01% 399
2024
Q3 		$11 Hold
2
– – ﹤0.01% 366
2024
Q2 		$11 Hold
2
– – ﹤0.01% 338
2024
Q1 		$14 Hold
2
– – ﹤0.01% 351
2023
Q4 		$17 Hold
2
– – ﹤0.01% 325
2023
Q3 		$19 Hold
2
– – ﹤0.01% 336
2023
Q2 		$26 Hold
2
– – ﹤0.01% 310
2023
Q1 		$33 Hold
2
– – ﹤0.01% 336
2022
Q4 		$31 Buy
+2
New +$38 ﹤0.01% 333

Other funds holding TTNP

CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
BWL
Bogart Wealth LLC Mclean, Virginia $2.92B AUM 23.85% 1-Year Est. Return
CSC
Caldwell Sutter Capital Sausalito, California $265M AUM 30.15% 1-Year Est. Return
DJSG
D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Global Wealth Strategies & Associates's TTNP Position: Q2 2026 in Review

Global Wealth Strategies & Associates sold out of Titan Pharmaceuticals (TTNP) in Q2 2026, closing a stake of 2 shares — an estimated $3 sold.

Global Wealth Strategies & Associates first reported a position in TTNP in Q4 2022 and held it in 14 quarters. The position peaked at $33 in Q1 2023. 5 funds tracked by Wall St. Rank hold TTNP as of Q2 2026.

  • Global Wealth Strategies & Associates reported no remaining Titan Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Global Wealth Strategies & Associates sold 2 Titan Pharmaceuticals shares in Q2 2026, an estimated $3.
  • Global Wealth Strategies & Associates first reported a position in Titan Pharmaceuticals in Q4 2022 and held it in 14 quarters.
  • Global Wealth Strategies & Associates's Titan Pharmaceuticals position peaked at $33 in Q1 2023.
  • 5 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q2 2026.

Based on Global Wealth Strategies & Associates's 13F filing for Q2 2026, filed 1 Jul 2026.